WO2006110593A3 - Biological targets for the diagnosis, treatment and prevention of cancer - Google Patents

Biological targets for the diagnosis, treatment and prevention of cancer Download PDF

Info

Publication number
WO2006110593A3
WO2006110593A3 PCT/US2006/013172 US2006013172W WO2006110593A3 WO 2006110593 A3 WO2006110593 A3 WO 2006110593A3 US 2006013172 W US2006013172 W US 2006013172W WO 2006110593 A3 WO2006110593 A3 WO 2006110593A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
prevention
expression
treatment
methods
Prior art date
Application number
PCT/US2006/013172
Other languages
French (fr)
Other versions
WO2006110593A2 (en
Inventor
Haller Priska D Von
Michel Schummer
David W Meyer
Lisa A Schubert
Larry W Tjoelker
Original Assignee
Macrogenics Inc
Haller Priska D Von
Michel Schummer
David W Meyer
Lisa A Schubert
Larry W Tjoelker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Haller Priska D Von, Michel Schummer, David W Meyer, Lisa A Schubert, Larry W Tjoelker filed Critical Macrogenics Inc
Publication of WO2006110593A2 publication Critical patent/WO2006110593A2/en
Publication of WO2006110593A3 publication Critical patent/WO2006110593A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods for detecting, diagnosing, monitoring and prognosing cancer by detecting differences in the expression of one or more, or any combination of the following genes: SLC12A2, FLJ23375, GRM5, TAS2R1, NRXN2, C14orfl60, MGC15668, MGC33486, TMEM16F, FAT, KIAA0195, LRFN, NFASC, BAT2D1, MGC2963, KIAA0685, EDG3, GGTL3, PLVAP, FLJ31528, FLJ90709, VEZATIN, TMPRSS9, ATP13A5, PKHDlLl, C2orfl8, ANKRD22, FAM62B, LOC57168, CDKALl, SLC39A3vl, SLC39A3v2, BAT5, TM9SF4, DC2, VAPB, XTP3TPB, TACSTD2, FNDC3A, GKOOl, OCIAD2, PRO1855, C20orf3, SDFRl, FLJ20481, LENG4, FLJ12443, ARP5 Long, ARP5 Short, TMD0645, NGEP, ILlRAPl, PLXNBl, ATP2B2, FLJl 1848, ENTPD2, PPMlH, KRTKAP3, KCNC3, TM9SF1, ULBPl, C19orf26, KIAA830, KIAA1244, KIAA1797, MGC26856, NETO2, SUSD2, FOLR2, EMR2, ENTPDl, ATPlOB, PTK7, FLJ14681, C20orf22, FLJ14281, FAM8A1, TMED7, C20orfl08, ATADl, GPR154, C14orf27, OSAP, FAD104, FLJ90492, SLC27A3, RON, ATP13A1, DKFZP564D166, ESSPL, EXTL3, KAIl, KIAA0960, MTRNL, SLC27A1, GRIA4, 0R4M1, KIAA1679 or UPK-Ib. The present invention also relates to methods for screening and identifying compounds that modulate the expression of one or more, or any combination of such genes. The invention further relates to the use of such compounds in the prevention, treatment, management and amelioration of cancer. The methods of the invention also comprise the administration of an effective amount of one or more therapies that modulate the expression and/or activity of one or more cancer targets disclosed herein for the prevention, treatment, management and amelioration of cancer.
PCT/US2006/013172 2005-04-07 2006-04-07 Biological targets for the diagnosis, treatment and prevention of cancer WO2006110593A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66934205P 2005-04-07 2005-04-07
US60/669,342 2005-04-07
US72598205P 2005-10-11 2005-10-11
US60/725,982 2005-10-11

Publications (2)

Publication Number Publication Date
WO2006110593A2 WO2006110593A2 (en) 2006-10-19
WO2006110593A3 true WO2006110593A3 (en) 2009-05-22

Family

ID=37087571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013172 WO2006110593A2 (en) 2005-04-07 2006-04-07 Biological targets for the diagnosis, treatment and prevention of cancer

Country Status (1)

Country Link
WO (1) WO2006110593A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN107419019A (en) * 2017-07-26 2017-12-01 湖北文理学院 Application of the TM9SF1 genes as target spot in vascular conditions

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4599541B2 (en) 2005-06-30 2010-12-15 タマティーエルオー株式会社 Malignant tumor cell inhibitory protein, malignant tumor cell inhibitory gene, malignant tumor cell inhibitory virus vector, and kit using the same
US7842466B1 (en) * 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
RS52804B (en) 2005-12-08 2013-10-31 Medarex Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
KR20090064378A (en) 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 Genes and polypeptides relating breast cancers
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) * 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US20100168382A1 (en) * 2007-06-12 2010-07-01 Vladimir Berezin Neuroplastin derived peptides
SG184763A1 (en) * 2007-06-18 2012-10-30 Agency Science Tech & Res Novel peptides and protein and uses thereof
AU2009207926B2 (en) * 2008-01-25 2014-06-19 Exosomics S.p.A. A new metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression
US20120058492A1 (en) * 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
RU2010141742A (en) * 2008-03-12 2012-04-20 Онкотерапи Сайенс, Инк. (Jp) C2orf18 AS TARGET GENE FOR THERAPY AND DIAGNOSTICS OF CANCER
DK2269071T3 (en) 2008-03-19 2015-01-05 China Synthetic Rubber Corp METHOD AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOM
EP2271673B1 (en) 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
JP5531228B2 (en) * 2008-03-28 2014-06-25 静岡県 Highly metastatic gastric cancer marker
EP2252631B1 (en) 2008-04-02 2016-04-13 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
CA2730710C (en) * 2008-07-24 2021-06-08 Nsgene A/S Therapeutic use of a growth factor, metrnl
DK2346904T3 (en) 2008-10-29 2017-06-12 China Synthetic Rubber Corp METHODS AND METHODS OF DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOM
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
US20120058131A1 (en) * 2009-01-21 2012-03-08 Oxford Biotherapeutics Ltd Pta089 protein
US8748390B2 (en) 2009-04-20 2014-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic epitopes of NGEP antigen
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
EP2621512B1 (en) 2010-10-01 2016-04-06 NsGene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CA2824719C (en) 2011-01-19 2020-06-02 Cantargia Ab Anti-il1rap antibodies and their use for treating solid tumours
EP2487242A1 (en) * 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
KR101212024B1 (en) 2011-08-08 2012-12-13 한국생명공학연구원 Biomarkers Indicative of Colon Cancer and Metastasis and Diagnosis and Screening Therapeutics Using the Same
CN104105501B (en) 2011-09-05 2017-10-20 霍巴治疗公司 Allodynia, hyperalgia, the treatment of spontaneous pain and phantom pain
WO2014071200A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of Colorado, A Body Corporate Beta blocker responder status assays and related materials and methods
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
RU2597782C1 (en) * 2015-08-25 2016-09-20 Василий Николаевич Яковлев Method of determining content of proteolysis products in blood plasma and diagnostic test system therefor
KR102514317B1 (en) 2016-04-15 2023-03-27 마크로제닉스, 인크. Novel B7-H3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3025377A1 (en) 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CN107177666A (en) * 2017-05-15 2017-09-19 中国医学科学院北京协和医院 Application of the gene as biomarker in adenocarcinoma of colon
CN107153116A (en) * 2017-06-05 2017-09-12 南通大学附属医院 FNDC3B purposes, the detection method for diagnosing FNDC3B expressions in the kit and lung tissue of adenocarcinoma of lung
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
EP3710054A4 (en) * 2017-11-18 2021-08-11 De Magalhaes, Nzola Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
PE20201286A1 (en) 2017-12-01 2020-11-24 Abbvie Inc GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES OF THIS
WO2021007527A1 (en) * 2019-07-11 2021-01-14 University Of Utah Research Foundation Compositions and methods for treating peroxisomal biogenesis disorders
CN110656166B (en) * 2019-09-17 2021-01-05 浙江大学 Application of ANKRD22 as target in preparation of gastrointestinal mucosa repair protective agent
CN113777309A (en) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129207A1 (en) * 2001-08-21 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030235820A1 (en) * 2001-02-27 2003-12-25 Eos Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20050064514A1 (en) * 2003-01-09 2005-03-24 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050260213A1 (en) * 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235820A1 (en) * 2001-02-27 2003-12-25 Eos Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
US20030129207A1 (en) * 2001-08-21 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20050064514A1 (en) * 2003-01-09 2005-03-24 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20050260213A1 (en) * 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN107419019A (en) * 2017-07-26 2017-12-01 湖北文理学院 Application of the TM9SF1 genes as target spot in vascular conditions
CN107419019B (en) * 2017-07-26 2018-09-14 湖北文理学院 Application of the TM9SF1 genes as target spot in vascular conditions

Also Published As

Publication number Publication date
WO2006110593A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006110593A3 (en) Biological targets for the diagnosis, treatment and prevention of cancer
Motomura et al. Benefits of interferon‐β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study
Kaur et al. Bromodomain and hedgehog pathway targets in small cell lung cancer
US20090099134A1 (en) Treatment of dna damage related disorders
Thomas DNA methylation in Huntington’s disease: Implications for transgenerational effects
Freudenberger et al. Genetics of age-related white matter lesions from linkage to genome wide association studies
Crake et al. The role of 2-oxoglutarate dependent dioxygenases in gliomas and glioblastomas: a review of epigenetic reprogramming and hypoxic response
Langie et al. Redox and epigenetic regulation of the APE1 gene in the hippocampus of piglets: the effect of early life exposures
Natsume et al. Epigenetic aberrations and therapeutic implications in gliomas
Takeiri et al. In vivo evidence that DNA polymerase kappa is responsible for error-free bypass across DNA cross-links induced by mitomycin C
Dyrvig et al. Epigenetic regulation of Dnmt3a and Arc gene expression after electroconvulsive stimulation in the rat
Amano et al. Opposite associations between the rs3845446 single-nucleotide polymorphism of the CACNA1E gene and postoperative pain-related phenotypes in gastrointestinal surgery versus previously reported orthognathic surgery
Ngwa et al. Aerobic exercise training-induced changes on DNA methylation in mild cognitively impaired elderly African Americans: gene, exercise, and memory study-GEMS-I
Allami et al. Genetic Association of Angiotensin-converting enzyme 2 ACE-2 (rs2285666) Polymorphism with the Susceptibility of COVID-19 Disease in Iraqi Patients.
WO2009140699A3 (en) ASTHMA SUSCEPTIBILITY LOCI LOCATED AT CHROMOSOME 1q31 FOR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS
Yamamura et al. NDRG2, suppressed expression associates with poor prognosis in pancreatic cancer, is hypermethylated in the second promoter in human gastrointestinal cancers
Alizadeh et al. The impact of EGCG and RG108 on SOCS1 promoter DNA methylation and expression in U937 leukemia cells
Mutti et al. Cobalamin deficiency-induced changes of epidermal growth factor (EGF)-receptor expression and EGF levels in rat spinal cord
Perreault et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia
WO2006097463A3 (en) Compositions and methods for treating and diagnosing inflammatory disorders
WO2006097462A3 (en) Compositions and methods for treating inflammatory cns disorders
Rasime Epigenetics of glioblastoma multiforme
WO2007071437A3 (en) Compositions and methods for treating inflammatory disorders
Wei et al. A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
WO2008098256A8 (en) Methods for identifying patients with an increased likelihood of responding to dpp-iv inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06758294

Country of ref document: EP

Kind code of ref document: A2